10-Q · May 8, 2026
Establishment Labs reported a notable Q1 2026 with revenue reaching $59.9 million, surpassing expectations and marking a 44.7% increase year-over-year. Despite an EPS loss of -$0.45, the company showed improvement in…
Earnings analysis · 10-Q
ESTA earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not contain the income statement, balance sheet, cash flow statement, segment data, or MD&A needed to assess Q2 financial trends. Controls were reported effective as of June 30, 2026, with…
Read full summary
The provided 10-Q extract does not contain the income statement, balance sheet, cash flow statement, segment data, or MD&A needed to assess Q2 financial trends. Controls were reported effective as of June 30, 2026, with no material changes in internal control. The principal disclosed negative is ongoing patent litigation, including UPC merits proceedings scheduled for December 2, 2026; management states that it cannot predict the ultimate outcome. The filing also states that there were no material changes to the risk factors from the February 27, 2026 Form 10-K.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls Remain Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, at the reasonable assurance level.
-
No Material Control Changes
The filing states that there was no change during the period covered by the 10-Q that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
Active Patent Enforcement
The company has filed infringement actions involving its SmoothSilk-related patents, including Patent No. BR112018072963-9 in Brazil and Patent No. EP 3 107 487 B1 in the Unified Patent Court.
What to watch
-
Patent Litigation Uncertainty
Patent disputes remain unresolved. The Unified Patent Court is scheduled to hold a case management hearing on September 21, 2026 and a merits hearing on December 2, 2026; the company states it cannot predict the ultimate outcome.
-
UK Patent Challenge
In the United Kingdom, GCA (Brazil) filed a patent revocation lawsuit on February 13, 2026, and a liability trial is expected in April 2027. The company warns that legal proceedings could adversely affect business, financial condition, results, or cash flows.
-
Planned Insider Share Sales
Two directors adopted Rule 10b5-1 plans covering up to 15,000 shares and 13,422 shares, respectively. The plans permit sales beginning August 25, 2026 and September 14, 2026, subject to pre-established price thresholds.
Management's outlook
The provided filing text does not include quantitative revenue or EPS outlook; numeric guidance may be disclosed in the earnings release or conference call.
Earlier filings 4
10-K · February 27, 2026
Establishment Labs’ 10-K describes a company transitioning from early commercialization to scaled growth: Motiva Implants commercialization in the U.S. (PMA approval Sept 2024, U.S. sales began Oct 2024) and new…
10-Q · November 7, 2025
Establishment Labs reported Q3 revenue of $53,782 (in thousands) and GAAP net loss of $(11,146) for the quarter (EPS $(0.38)), with strong margin expansion and a narrower operating loss versus the prior year. Gross…
10-Q · August 7, 2025
Establishment Labs reported quarterly revenue of $51,300,000 for the three months ended June 30, 2025, up from $44,117,000 a year earlier, with gross profit rising to $35,272,000 (68.8% gross margin). The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.